ISRG Stock: The Best House On The Block Costs The Most
In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.
Intuitive Surgical (ISRG), the pioneer of robotic-assisted surgery, trades around $370, a share after a tough year. The stock has delivered a -21% return over the last twelve months, badly trailing the S&P 500’s +19.2% gain. Yet, within its peer group, it commands the highest valuation. Why does the market charge a top-tier price for the company with the group’s worst-performing stock?
Why Does the Best Operator Have the Worst-Performing Stock?
By the numbers, Intuitive Surgical’s operational lead is real, even if Globus Medical sits close behind at 19.7%. The company’s revenue grew 21% over the last twelve months, well ahead of diversified rivals like Medtronic, which grew at 8.4%.. Its 31% operating margin also leads the pack, again comfortably ahead of Medtronic’s 18.8%. This is a business that executes at a higher level than its competition. The market sees this performance and charges accordingly. Intuitive Surgical trades at 42.5 times earnings, the highest multiple in its group. For comparison, Medtronic trades at a much lower 24.2 times earnings. The mismatch is stark: investors are paying a premium for leading fundamentals, but so far, that premium has not translated into positive returns.
| ISRG | MDT | JNJ | SYK | ZBH | GMED | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 133.4 | 116.1 | 640.0 | 124.2 | 19.2 | 11.0 |
| PE Ratio | 42.5 | 24.2 | 30.4 | 33.3 | 23.8 | 20.5 |
| LTM Revenue Growth | 21% | 8.4% | 8.1% | 8.5% | 8.6% | 19.7% |
| LTM Operating Margin | 31% | 18.8% | 27% | 22% | 16.3% | 21% |
| 12M Stock Return | -21% | 1.8% | 55% | -16.1% | -3.8% | 33% |
The Market is Paying for a Powerful Upgrade Cycle
The bull case for Intuitive’s valuation rests on the powerful demand for its new technology, particularly the da Vinci 5 system. The company’s capital equipment sales are strong, suggesting hospitals are confident in the platform’s long-term value. In the second quarter, Intuitive placed 468 da Vinci systems, with management noting that 246 of those placements were da Vinci 5 systems. This suggests a healthy upgrade cycle is underway. Growth is also solid overseas, with procedure volume growing 20% outside the U.S.
- Can ISRG Stock Defend Its $131B Valuation?
- The Hospital Bet That Reframes The Intuitive Surgical Stock Story
- Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening
- S&P 500 Movers | Winners: NDSN, COIN, DE | Losers: MRNA, WMT, ISRG
- Can ISRG Stock Survive A Drop To $280?
- The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income
This global expansion provides a crucial offset to a more mature domestic market. The durability of the company’s high valuation is a key question for investors, as some analysts have explored whether the stock can defend its market capitalization. The honest catch, however, is that the U.S. market is showing signs of slowing. Management noted that “Growth in the US moderated from recent trends,” attributing it to changes in patient insurance coverage affecting deferrable procedures. The market’s fear is that this isn’t a temporary blip but a sign of market maturation, a risk that justifies the stock’s recent underperformance.
What to Watch: Will Procedure Growth Hold Its 13.5% to 15.5% Guided Range?
The debate boils down to whether the strength of the da Vinci 5 cycle and international adoption can overcome the slowdown in U.S. procedure growth. While the new system is clearly a success, the company’s recurring revenue is driven by the number of procedures performed. For investors who prefer to own the entire theme of medical technology advancement, a healthcare ETF like XLV offers broader exposure. Ultimately, the test of Intuitive Surgical’s premium valuation lies in its ability to meet its own targets for that core metric. Management has affirmed its full-year forecast for worldwide da Vinci procedure growth to be within a range of 13.5% to 15.5%. If the company finishes the year within this guided range, it would validate the bull case that the U.S. slowdown is manageable. A miss, or a future downward revision, would signal that the market’s concerns were justified all along.
To keep score on this group beyond today, our full peer-by-peer dashboards for ISRG track the whole lineup, metric by metric.
Even The Best Of The Group Is Still One Stock
Whichever name wins a peer comparison, buying it concentrates you in one company and one industry, and industries move together: when the group catches a cold, the best house on the block still sneezes.
The Trefis High Quality (HQ) Portfolio diversifies across roughly 30 quality names in different industries, selected on fundamentals and re-balanced with discipline, so no single group’s weather decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the comparison to understand the stock; use the portfolio to own the market’s best.